Page 161 - நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

by Barry Teater, NCBiotech writer February 16, 2021 . RESEARCH TRIANGLE PARK – After 13 years as a clinical-stage oncology company, G1 Therapeutics of Research Triangle Park transformed into a commercial-stage company overnight upon the approval of its first drug by the U.S. Food and Drug Administration. The FDA on Feb. 12 approved G1’s trilaciclib, to be marketed as Cosela, for protecting bone marrow from chemotherapy damage in adult patients with extensive-stage small cell lung cancer (ES-SCLC). “Cosela will help change the chemotherapy experience for people who are battling ES-SCLC,” said Jack Bailey, the company’s chief executive officer. “G1 is proud to deliver Cosela to patients and their families as the first and only therapy to help protect against chemotherapy-induced myelosuppression.”

Puerto ricoUnited statesNorth carolinaUniversity of north carolinaResearch triangle parkJeffrey crawfordJack baileyBonniej addarioDuke cancer instituteCarolina biotechnology centerBoehringer ingelheimResearch in cancerDrug administrationUniversity of north carolina at chapel hillTherapeutics of research triangle parkFoundation for lung cancer